Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508938 | 0.80 | MAOB (0.59) | NPC1RAB9AMAOBMAOAKDM4E | |
| SCHEMBL103158 | 0.75 | MAOB (0.63) | NPC1RAB9AMAOBMAOAADRA2A | |
| SCHEMBL30036439 | 0.75 | MAOB (0.63) | NPC1RAB9AMAOBMAOAADRA2A | |
| SCHEMBL1018789 | 0.72 | ALOX5 (0.46) | NPC1RAB9AMAOBMAOAADRA2A | |
| SCHEMBL2150499 | 0.71 | MAOB (0.59) | NPC1RAB9AMAOBMAOAADRA2A | |
| SCHEMBL9537233 | 0.71 | ALOX5 (0.45) | NPC1RAB9AMAOBMAOAADRA2A | |
| SCHEMBL1257288 | 0.70 | RAB9A (0.52) | NPC1RAB9AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL3071818 | 0.70 | CTSV (0.44) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Carbazole SCHEMBL29214629 | 0.70 | MAOB (0.54) | NPC1RAB9AMAOBMAOAADRA2A | |
| SCHEMBL2149640 | 0.69 | MAOB (0.57) | NPC1RAB9AMAOBMAOAADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336131-A1 | Hydantoin compounds | Eisai R&D Management Co., Ltd. (JP) | 2011-06-22 | — | — | EP | claimed |
| EP-2522394-A2 | Substituted phosphonates and their use decreasing amyloid aggregates | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-11-14 | — | — | EP | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012978-B2 | Prodrugs of CC-A1065 analogs | IMMUNOGEN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7906545-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2238988-A1 | Conjugated prodrugs of cc-1065 analogs | ImmunoGen, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| EP-1492526-B1 | CONJUGATED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN INC (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7655661-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-6756397-B2 | SUCH AS (S)-N-(2-((1-CHLOROMETHYL)-1,2-DIHYDRO-5-((4-METHYLPIPERAZINO)CARBONYLOXY) -3H-BENZ(E) INDOL-3-YL)CARBONYL)-1H-INDOL-5-YL)-5-((3-METHYLDITHIO-1-OXOPROPYL)-AMINO) -1H-INDOLE-2-CARBOXAMIDE; ENHANCED WATER SOLUBILITY AND STABILITY | IMMUNOGEN, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040109867-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2003086318-A2 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2003-10-23 | — | — | US | disclosed |
| EP-0563475-B1 | Cell binding agent conjugates of derivatives of CC-1065 | IMMUNOGEN INC (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5846545-A | Targeted delivery of cyclopropylbenzindole-containing cytotoxic drugs | IMMUNOGEN, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0541168-B1 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO INC (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5585499-A | DRUG DELIVERY | IMMUNOGEN INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5475092-A | Deliver cytotoxic drugs to specific cell population in targeted fashion | IMMUNOGEN INC. (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0563475-A1 | Cell binding agent conjugates of derivatives of CC-1065 | IMMUNOGEN INC (US) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, SENP5, CWC15 | NPC1 2136/4885RAB9A 3993/4885MAOB 4819/4885 |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | NPC1 2467/4885RAB9A 3531/4885MAOB 4641/4885 |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, DNPEP, PRCP | NPC1 2467/4885RAB9A 3531/4885MAOB 4641/4885 |
| US-20040109867-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | NPC1 2467/4885RAB9A 3531/4885MAOB 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.